RevMed (RVMD) - Market Capitalization to Book Value Ratio

Corporate emblem and logo of RevMed (RVMD)

This daily price chart for Revolution Medicines (RVMD) illustrates market expectations for the oncology therapy developer, where the current metric stands at 15.41. Due to a lack of sales and high R&D expenditures, the company lacks profit and a stable cash flow. However, unique patents provide a technological edge over competitors, and the success of clinical trials will enable the company to unilaterally exercise pricing power for its drugs in the future.

Revolution Medicines (RVMD) - Market Capitalization to Book Value Ratio from 07/04/2022 to 10/29/2026

Analytical breakdowns and data insights for company Revolution Medicines Inc (RVMD)

- share price and expert price forecast:
Stock Price Revolution Medicines|RVMD - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization RevMed|RVMD - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Book Value per Share Revolution Medicines|RVMD - Book Capitalization|Market Value to Book Value Ratio revmed.com|RVMD - Total Business Assets
- debt and liquidity details:
Total Debt to Capital Revolution Medicines|RVMD - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital RevMed|RVMD - Company Cumulative Debt|Debt to Book Capitalization Ratio RevMed|RVMD - Company Long-Term Loans and Borrowings|Company Current Liabilities Revolution Medicines
Comprehensive company analysis:Revolution Medicines
Flagship merchandise of Revolution Medicines Inc

The current P/BV multiple of Revolution Medicines (RVMD) reflects the market's revaluation of the company's intellectual assets, as its scaling model relies on the high margins of patented oncology drugs. This indicator compares the business's market value with its net assets, making it possible to determine whether a low price results from undervaluation or is a sign of systemic capital impairment, which is critical for risk assessment in the biotech sector.

Who Revolution Medicines competes with

ONC: Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio HALO|AAPG (Ascentage Pharma) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio CG Oncology Inc (CGON)|Market Capitalization to Book Value Ratio URGN|Market Capitalization to Book Value Ratio Bicara Corp (BCAX)|Market Value to Book Value Ratio Personalis, Inc. PSNL|ERAS: Capitalization to Book Value Ratio|Delcath Systems - Market Capitalization to Book Value Ratio|Y-mAbs Therapeutics Inc (YMAB) - Market Cap to Net Assets Ratio|AURA: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Candel Therapeutics, Inc. (CADL)|Market Value to Book Value Ratio Accuray Incorporated|SLS: Market Value to Book Value|Market Cap to Net Assets Ratio ACTU (Actuate Therapeutics)|CTOR (Citius Oncology Inc.) - Market Value to Book Value|Market Capitalization to Book Value Ratio HURA (TuHURA Biosciences)|TARA - Market Cap to Net Assets Ratio|FATE: Market Cap to Net Assets Ratio|WHWK - Market Capitalization to Book Value Ratio|tscan.com (TCRX) - Market Value to Book Value Ratio|Champions Oncology, Inc. - Market Value to Book Value|XBIT (XBiotech Inc) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio CEL-SCI Corp CVM|Market Value to Book Value Ratio OS Therapies Incorporated (OSTX)|RADX (Radiopharm Theranostics Ltd) - Market Value to Book Value|Market Capitalization to Book Value Ratio ARTV (Artiva Biotherapeutics)|Adlai Nortye Ltd (ANL) - Market-to-Book Ratio|VERU: Market Cap to Net Assets Ratio|TPST: Market Value to Book Value Ratio|xiliotx.com (XLO) - Market Value to Book Value Ratio|Market-to-Book Ratio Renovaro (RENB)|Market Value to Book Value Ratio Mural Oncology PLC|Market Value to Book Value Ratio KAPA|Market Cap to Net Assets Ratio OKUR (OnKure Therapeutics Inc)|Market Capitalization to Book Value Ratio w2.cytomed.sg (GDTC)|Curis - Market Cap to Net Assets Ratio|Market Cap to Book Value Multiple APLM (Apollomics Inc.)|Tharimmune - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Advanced Biomed Inc ADVB|Genprex, Inc (GNPX) - Market Value to Book Value Ratio|Market-to-Book Ratio Calidi Biotherapeutics, Inc. (CLDI)|Market Value to Book Value Ratio Sunshine Biopharma|Capitalization to Book Value Ratio XBIO (Xenetic Bio)|Market Cap to Net Assets Ratio SLRX (Salarius Pharmaceuticals, Inc.)|PPBT (Purple Biotech Ltd) - Market Value to Book Value|Market Value to Book Value Ratio American Oncology Network, Inc. AONC|BGNE - Market Cap to Net Assets Ratio|Checkpoint Therapeutics - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Elevation Oncology Inc.|ICAD: Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio IKNA|NTBL (Notable Labs Inc.) - Market Capitalization to Book Value Ratio|Viracta (VIRX) - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio MOR|Market Cap to Net Assets Ratio nayabiosciences.com NAYA|Market Capitalization to Book Value Ratio AAPGV (Ascentage Pharma)